Clinical Trials

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.

AstraZeneca’s AZD1222 vaccine demonstrates promising efficacy

AstraZeneca announced that its AZD1222 vaccine has demonstrated a significant effect in preventing Covid-19 in an interim analysis of clinical trials in the UK and Brazil.

Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of Covid-19.

Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

Pfizer and BioNTech have announced that their BNT162b2 Covid-19 vaccine candidate has achieved all primary efficacy endpoints in the phase 3 study.

Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.

Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

Merck announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP) option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa.

Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

Moderna announced that its mRNA-1273 Covid-19 vaccine candidate has shown a significant effect against Covid-19 patients in phase 3 COVE study.

Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio has secured approval from the US Food & Drug Administration (FDA) to begin phase 2 segment of its planned phase 2/3 clinical trial for its Covid-19 DNA vaccine candidate.

Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis

Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the first patient in the phase II idiopathic pulmonary fibrosis (IPF) study has been recruited in India.